Innate Pharma S.A. ADS (IPHA) — Analysis Summary
Innate Pharma S.A. ADS (IPHA) has a market cap of $249.09M with year-over-year revenue growth of -53.2%. Net margin stands at -546.1%. The stock trades at a P/E ratio of -4.5.
Key Takeaways
- Revenue changed -53.2% year-over-year
- Net margin of -546.1%
- P/E ratio of -4.5
Compared with its sector, IPHA posted revenue growth of -53.2% and trades at a P/E of -4.5.
Innate Pharma S.A. ADS (IPHA)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -122.7x — earnings do not cover interest payments
Operating margin at -599.8% — severe operating losses
Net margin at -546.1% — losses exceed revenue (possible one-time charges)
Shareholder equity is negative, which can signal balance-sheet stress.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Employees
163
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.